Ellipses’ next generation selective RET inhibitor EP0031 advances to Phase 2 clinical trials in the USA.
Clinical study for patients with RET+ solid tumors
EP0031 is a new specific RET inhibitor with broad activity against common RET fusions and mutations, including RET mutations that confer resistance to the RET inhibitors selpercatinib or pralsetinib and great brain penetration.
More info:
https://clinicaltrials.gov/
